- Prescribing Advice for GPs - https://www.prescriber.org.uk -

MTRAC Reviews - March 2014

MTRAC issued two new Commissioning Support reviews in March 2014. The reviews cover denosumab and rifaximin.

The denosumab (Prolia®) summary advises that this drug is suitable for restricted prescribing in primary care, following secondary care initiation and stabilisation of treatment. The review notes that this medicine has relatively strong evidence but a lower place in therapy as recommended by NICE guidance.

The rifaximin (Targaxan®) summary advises that this drug is suitable for restricted prescribing in primary care, following secondary care initiation and stabilisation and with the guidance of a shared care agreement. The review notes that this medicine has relatively strong evidence but a lower place in therapy after existing treatment options were inadequate or inappropriate.

Action: Clinicians should be aware of these reviews and use the recommendations to guide appropriate use of these medicines in current practice.